Targeting micro-environmental pathways by PROTACs as a therapeutic strategy.

Abstract

Tumor microenvironment (TME) composes of multiple cell types and non-cellular components, which supports the proliferation, metastasis and immune surveillance evasion of tumor cells, as well as accounts for the resistance to therapies. Therefore, therapeutic strategies using small molecule inhibitors (SMIs) and antibodies to block potential targets in TME are practical for cancer treatment. Targeted protein degradation using PROteolysis-TArgeting Chimera (PROTAC) technic has several advantages over traditional SMIs and antibodies, including overcoming drug resistance. Thus many PROTACs are currently under development for cancer treatment. In this review, we summarize the recent progress of PROTAC development that target TME pathways and propose the potential direction of future PROTAC technique to advance as novel cancer treatment options.

• Authors: Jing Liu, Yunhua Peng, Hiroyuki Inuzuka, Wenyi Wei
• Journal: Seminars in cancer biology (Semin Cancer Biol) Vol. 86 Issue Pt 2 Pg. 269-279 (11 2022) ISSN: 1096-3650 [Electronic] England
• PMID: 35798235 (Publication Type: Journal Article, Review, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2022 Elsevier Ltd. All rights reserved.

Chemical References

• Ubiquitin-Protein Ligases

Topics

• Humans
• Drug Discovery (methods)
• Proteolysis
• Neoplasms (drug therapy, pathology)
• Ubiquitin-Protein Ligases (metabolism)
• Tumor Microenvironment